Pathologies: reimbursed expenditure allocated to each pathology

Open data API in a single place

Provided by Caisse nationale de l'Assurance Maladie (Cnam)

Get early access to Pathologies: reimbursed expenditure allocated to each pathology API!

Let us know and we will figure it out for you.

Dataset information

Country of origin
Updated
2025.12.15 15:11
Created
2025.12.15
Available languages
English
Keywords
pathologies
Quality scoring

Dataset description

This dataset is one of the sources of data visualisations available on the website [Data pathologies](https://data.ameli.fr/pages/data-pathologies/). ### Updated on 10/07/2023: update of data from 2015 to 2021 The data history has been updated: * data from **2015 to 2020 have been updated** * data for **2021 are now available** This new version of the data (July 2023) replaces the previous version (dating from June 2022). ### General information: The data present information on the expenses reimbursed by all health insurance schemes and allocated to each pathology, chronic treatment or episode of care. This expenditure shall be divided between: * city care (including medical care, nursing or physiotherapy, medicine, biology, transport, etc.); * hospitalisations in public or private health facilities; * cash benefits (including daily allowances). Pathologies, chronic treatments and episodes of care are grouped into the following categories: * cardio-neurovascular diseases; * vascular risk treatments (excluding cardiovascular diseases); * diabetes; * cancers; * psychiatric pathologies; * psychotropic treatment (excluding psychiatric diseases); * neurological and degenerative diseases; * chronic respiratory diseases; * inflammatory or rare diseases or human immunodeficiency virus (HIV) or AIDS; * chronic terminal renal impairment (CTRD); * liver or pancreatic diseases; * other long-term conditions (ALD 31 and 32); * stays in full hospitalisation to take care of Covid-19 (from 2020); * maternity; * chronic treatments with analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids; * punctual hospital stays. The expenses reimbursed for persons who do not have any of the conditions, chronic treatments or episodes of care mentioned above are also presented, as well as those attributed to the daily consumption of care for the entire population of the mapping of pathologies and expenses of the Sickness Insurance. The proposed expenditure is of different types: * total annual expenses reimbursed (per year); * average annual expenses reimbursed (per year and per patient). Patient numbers are also presented in the data. The reference population is that of mapping the pathologies and expenditure of Sickness Insurance. ### What is Health Insurance’s Pathology and Expenditure Mapping Population? The mapping population lists all beneficiaries of compulsory health insurance, regardless of their membership scheme: * having received at least one benefit in the year (medical care, nursing or physiotherapy, medicine, biology, transport, etc.); * and/or having stayed at least once in a public or private health facility during the year (stays in medicine, surgery, obstetrics, psychiatry, follow-up and rehabilitation care, outpatient procedures and consultations or in-home hospitalisation). In 2021, it brings together 68.7 million beneficiaries from all health insurance schemes, who have used reimbursed care. This population is used by the Caisse nationale de l’assurance Maladie (Cnam) to carry out numerous studies and produce data on the pathologies and expenditure of sickness insurance. For more information, see the [Method](https://observatoirepathologies-cnam.opendatasoft.com/pages/methode/) page of this site. ### Statistical confidentiality: Out of respect for statistical confidentiality (Law of 7 June 1951) and in order to make it impossible to identify individuals directly or indirectly, no information on numbers of patients is provided when the number of patients in care is less than 11. The value of the indicator is then indicated by the variable “NS” (not significant) in the dataset and set to “Not significant” in the graphical representations. ### Data update: The data proposed for download in the “Export” tab is updated every year (data from the whole of France from 2015 to 2021).
European data infrastructure with broad catalog discovery, free evaluation access and production-grade API options.
190K+
indexed dataset pages
32
countries and EU institutions
2019
API-first since
Free API quota
for evaluation and prototypes
SLA
history and push on production APIs
FAQ

Questions before production use

Practical answers on evaluation, licensing, freshness, versioning and support.

api.store is built and operated by Apitalks s.r.o. Company details and a direct contact path are linked in the footer for vendor checks and procurement review.
Yes. Selected APIs include a free API quota, so your team can validate coverage, freshness, response shape and workflow fit before asking for a production plan.
Often yes, but usage rights depend on the source license and dataset. We surface source, license and update metadata where available, and can help review terms before a production integration.
Maintained APIs include update metadata where available. For production integrations, we can add history, monitoring and push updates so changes are easier to detect and act on.
Production APIs can add SLA, stable identifiers, versioning support, history, push updates and direct support around the data your product or AI workflow depends on.

Didn't find the API you need?

Let us know and we will figure it out for you.

European data discovery with free evaluation access and production-grade API options.

Copyright © 2026. Made by Apitalks